SHORT ADMINISTRATION OF METFORMIN IMPROVES INSULIN SENSITIVITY IN ANDROID OBESE SUBJECTS WITH IMPAIRED GLUCOSE-TOLERANCE

被引:21
作者
SCHEEN, AJ
LETIEXHE, MR
LEFEBVRE, PJ
机构
[1] Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liège
关键词
IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; METFORMIN; MINIMAL MODEL OBESITY;
D O I
10.1111/j.1464-5491.1995.tb00410.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In a double-blind, randomized, cross-over study, the metabolic effects of a short treatment with metformin (2 x 850 mg day(-1) for 2 days and 850 mg 1 h before evaluation) were compared to those of placebo in 15 obese subjects (BMI: 33.2 +/- 0.9 kg m(-2)), with abdominal distribution of adipose tissue and impaired glucose tolerance. An intravenous glucose tolerance test (0.3 g glucose kg(-1)) was performed after each period of treatment. Areas under the curve (AUC(0-180 min)) were calculated for plasma glucose, insulin, and C-peptide levels. Glucose tolerance was estimated by the coefficient of glucose assimilation (K-G). Insulin sensitivity (S-I) and glucose effectiveness (S-G) indices were calculated using Bergman's minimal model. Insulin secretion rate (ISR) was determined by deconvolution of plasma C-peptide levels and insulin metabolic clearance rate (MCR) was estimated by dividing AUC ISR by AUC insulin. Easting plasma insulin levels were reduced after metformin (89.3 +/- 15.9 vs 112.4 +/- 24.3 pmol l(-1); p = 0.04). AUC glucose, K-G and S-G were similar in both tests. However, AUC insulin was reduced (39.7 +/- 6.5 vs 51.8 +/- 10.4 nmol min l(-1); p = 0.02), while S-I (6.98 +/- 1.14 vs 4.61 +/- 0.42 10(-5) min(-1) pmol(-1) l; p = 0.03) and insulin MCR (715 +/- 116 vs 617 +/- 94 ml min(-1) m(-2); p = 0.03) were increased after metformin. The demonstration that metformin rapidly improves insulin sensitivity should encourage further research to evaluate the long-term effects of metformin in android obese subjects with impaired oral glucose tolerance.
引用
收藏
页码:985 / 989
页数:5
相关论文
共 37 条
[21]  
Letiexhe MR, Scheen AJ, Gerard PL, Desaive C., Lefebvre PJ, Insulin secretion, clearance and action before and after gastroplasty in severely obese subjects, Int J Obesity, 18, pp. 295-300, (1994)
[22]  
Castillo MJ, Scheen AJ, Letiexhe MR, Lefebvre PJ, How to measure insulin clearance, Diabetes Metab Rev, 10, pp. 119-150, (1994)
[23]  
Bergman RN, Towards physiological understanding of glucose tolerance. Minimal‐model approach, Diabetes, 38, pp. 1512-1527, (1989)
[24]  
Scheen AJ, Paquot N., Castillo MJ, Lefebvre PJ, How to measure insulin action in vivo, Diabetes Metab Rev, 10, pp. 151-158, (1994)
[25]  
Zerbe GO, Randomization analysis of the completely randomized design extended to growth and response curves, Journal of the American Statistical Association, 74, pp. 215-221, (1979)
[26]  
Giugliano D., de Rosa N., Di Maro G., Marfella R., Acampora R., Buoninconti R., Et al., Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women, Diabetes Care, 16, pp. 1387-1390, (1993)
[27]  
Landin K., Tengborn L., Smith U., Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors, J Internal Med, 229, pp. 181-187, (1991)
[28]  
Saad MF, Anderson RL, Laws A., Watanabe RM, Kades WW, Chen Y-DI, Et al., A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance, Diabetes, 43, pp. 1114-1121, (1994)
[29]  
Perriello G., Misericordia P., Volpi E., Santucci A., Santucci C., Ferrannini E., Et al., Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production, Diabetes, 43, pp. 920-928, (1994)
[30]  
Haffner SM, Stern MP, Watanabe RN, Bergman RN, Relationship of insulin clearance and secretion to insulin sensitivity in non‐diabetic Mexican Americans, Eur J Clin Invest, 22, pp. 147-153, (1992)